Clinical Trial

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

Study acronym: VICD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label phase II study with a safety lead-in phase.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-01-22; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Recruiting 2021-11-02
Trial Details
NCT Number NCT04240054
Lead Sponsor Medical College of Wisconsin
Conditions Multiple Myeloma
Enrollment 41 participants
Start Date 2021-11-02
Primary Completion 2029-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-28